180 related articles for article (PubMed ID: 37845557)
1. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.
Shirwaikar Thomas A; Chari ST
Curr Gastroenterol Rep; 2023 Oct; 25(10):255-259. PubMed ID: 37845557
[TBL] [Abstract][Full Text] [Related]
2. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
Ashkar M; Chandra S; Vege SS; Takahashi H; Takahashi N; McWilliams RR
Cancer Immunol Immunother; 2023 Apr; 72(4):895-901. PubMed ID: 36161510
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Gupta R; Neyaz A; Chougule A; Akita M; Zen Y; Forcione D; Castillo CF; Ferrone CR; Deshpande V
Am J Surg Pathol; 2019 Jul; 43(7):898-906. PubMed ID: 31135488
[TBL] [Abstract][Full Text] [Related]
7. Steroid Therapy and Steroid Response in Autoimmune Pancreatitis.
Matsubayashi H; Ishiwatari H; Imai K; Kishida Y; Ito S; Hotta K; Yabuuchi Y; Yoshida M; Kakushima N; Takizawa K; Kawata N; Ono H
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905944
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic adverse events in patients treated with immune checkpoint inhibitors.
Hana C; Rehman T; Park K; Carracedo Uribe C; Aung PP; Hunis B; Salzberg M; Zikria J; Hussein A
JGH Open; 2023 Mar; 7(3):204-207. PubMed ID: 36968572
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging.
Thomas AS; Abreo M; Sayed SA; Sireesha Yedururi YW; Chari ST
Gastroenterology; 2023 Jan; 164(1):154-155. PubMed ID: 36220459
[No Abstract] [Full Text] [Related]
10. Sialadenitis in a patient with ulcerative colitis and autoimmune pancreatitis type 2.
Detlefsen S; Olesen SS
Pathol Res Pract; 2020 Sep; 216(9):153072. PubMed ID: 32825945
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract][Full Text] [Related]
13. [A young woman with auto-immune pancreatitis].
Zoutendijk R; van Santvoort HC; Raicu MG; Bollen TL; Verdonk RC
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36928874
[TBL] [Abstract][Full Text] [Related]
14. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer.
Chari ST; Takahashi N; Levy MJ; Smyrk TC; Clain JE; Pearson RK; Petersen BT; Topazian MA; Vege SS
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1097-103. PubMed ID: 19410017
[TBL] [Abstract][Full Text] [Related]
15. Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus.
Noguchi K; Nakai Y; Mizuno S; Isayama H; Hirano K; Kanai S; Nakamura T; Uchino R; Takahara N; Kogure H; Tada M; Koike K
J Gastroenterol; 2020 Feb; 55(2):198-204. PubMed ID: 31471733
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
17. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
18. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract][Full Text] [Related]
20. Imaging findings of immune checkpoint inhibitor associated pancreatitis.
Das JP; Postow MA; Friedman CF; Do RK; Halpenny DF
Eur J Radiol; 2020 Oct; 131():109250. PubMed ID: 32905952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]